Table 3. Adverse event summary.
Combination (n=43) | Valsartan (n=41) | Rosuvastatin (n=37) | p | |
---|---|---|---|---|
Any adverse events | 15 | 11 | 7 | |
Number of subjects who experienced AEs | 10 (23.3 ) | 7 (17.1 ) | 4 (10.8 ) | 0.34 |
Number of subjects who experienced SAEs | 1 (2.3 ) | 0 (0 ) | 0 (0 ) | 1.00 |
AE: adverse event, SAE: serious adverse event